% | $
Quotes you view appear here for quick access.

Endocyte, Inc. Message Board

  • sunshinecamesoftly2002 sunshinecamesoftly2002 Jun 29, 2013 9:15 PM Flag

    ECYT on the Move 2nd Half 2013

    The second half of 2013 will determine ECYTs growth. With 2 late stage trials in Ovarian CA and Lung CA and a low equity value at this stage we could really grow substantially with a European Preliminary approval for Ovarian CA. In addition with the prostate trial starting with tubulysin and an ovarian trial with tubulysin targeted for 2H 2013 we could really gain some notice. ECYT value has grown this year but with a market cap of 450 million on hand and a 150 million in cash they are still undervalued.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.99-0.03(-0.99%)Aug 26 4:00 PMEDT